Kwende Smith, DPM
Podiatrist · Taunton, MANPI 1205875341
Payments from drug & device makers
Across 28 payments — averaging $18.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organogenesis Inc.$125
- Smith+Nephew$120
- Acera Surgical, Inc.$83
- AbbVie$25
- Kerecis Limited$24
- Convatec Inc.$22
- plus $114 from 7 others
What the payments were for
- Food & beverage$513100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organogenesis Inc. | 6 | $125 |
| Smith+Nephew | 8 | $120 |
| Acera Surgical, Inc. | 2 | $83 |
| AbbVie | 1 | $25 |
| Kerecis Limited | 2 | $24 |
| Convatec Inc. | 1 | $22 |
| Integra Lifesciences Corporation | 1 | $22 |
| Misonix Inc | 1 | $22 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Merck | 1 | $16 |
| Melinta Therapeutics, LLC | 1 | $14 |
| Advanced Oxygen Therapy Inc. | 2 | $11 |
| Osiris Therapeutics Inc. | 1 | $11 |
How this compares
$513 in reported general payments places this provider in the 50th percentile of 179 podiatrist providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SantylCollagenase Clostridium Hist. | 13 | $6,586 |
| Linezolid | 18 | $1,409 |
| Doxycycline Hyclate | 44 | $361 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 18 | $319 |
| Diclofenac Potassium | 24 | $293 |
| Terbinafine Hcl | 12 | $128 |
| Cephalexin | 26 | $126 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $121 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl | $120 | $6,58613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 179 podiatrist providers in Massachusetts.
Other podiatrist in Taunton
- Pasquale CancelliereSomerville$374K
- Michael TheodoulouSomerville$210K
- Sara Rose-SauldWaltham$92K
- Jonathan KaplanWellesley$56K
- Thanh DinhBoston$48K
- Melissa RicciMilton$46K
- Jeffrey PantanoMilton$46K
- Barry RosenblumBoston$43K
- Louis DecaroWest Hatfield$19K
- Daren BergmanFramingham$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.